These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27123743)

  • 21. Rapid immunization effects of a new type of 60 μg hepatitis B vaccine compared with traditional 20 μg hepatitis B vaccines in adults.
    Wang H; Cai B; Rao D; Liu M; Li Y; Liang X; Cui F; Zhang G; Wang F; Pang X; Nie L; Qiu Q; Wu J; Li L; Huang F; Zhang W
    Hum Vaccin Immunother; 2016 Nov; 12(11):2921-2926. PubMed ID: 27648684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
    Vesikari T; Langley JM; Segall N; Ward BJ; Cooper C; Poliquin G; Smith B; Gantt S; McElhaney JE; Dionne M; van Damme P; Leroux-Roels I; Leroux-Roels G; Machluf N; Spaans JN; Yassin-Rajkumar B; Anderson DE; Popovic V; Diaz-Mitoma F;
    Lancet Infect Dis; 2021 Sep; 21(9):1271-1281. PubMed ID: 33989539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
    Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
    Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
    Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
    J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.
    Avdicova M; Crasta PD; Hardt K; Kovac M
    Vaccine; 2015 May; 33(23):2727-33. PubMed ID: 24962750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
    Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B.
    Martins RM; Bensabath G; Arraes LC; Oliveira Mde L; Miguel JC; Barbosa GG; Camacho LA
    Mem Inst Oswaldo Cruz; 2004 Dec; 99(8):865-71. PubMed ID: 15761604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates.
    Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R
    Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of immunity in healthy adults aged ≥ 50 years primed with a hepatitis B vaccine 3 years previously.
    Sharma R; Ahlm C; Ostergaard L; Dowell A; Tran C; Thomas S; Eymin C
    Hum Vaccin Immunother; 2015; 11(7):1709-16. PubMed ID: 25996838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules in healthy young adults in China.
    Wang ZZ; Li MQ; Wang P; Yang ZX; Wei L; Zeng Y; Li YP; Yan L; Liu XE; Zhuang H
    Vaccine; 2016 Feb; 34(8):1034-9. PubMed ID: 26801063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers.
    De Schryver A; Verstrepen K; Vandersmissen L; Vandermeeren N; Vernaillen I; Vranckx R; Van Damme P; van Sprundel M
    J Viral Hepat; 2011 Apr; 18(4):e5-10. PubMed ID: 20735800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
    Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ
    Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience.
    Van Den Ende C; Marano C; Van Ahee A; Bunge EM; De Moerlooze L
    Expert Rev Vaccines; 2017 Aug; 16(8):811-832. PubMed ID: 28573913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.
    Minervini G; McCarson BJ; Reisinger KS; Martin JC; Stek JE; Atkins BM; Nadig KB; Liska V; Schödel FP; Bhuyan PK
    Vaccine; 2012 Feb; 30(8):1476-80. PubMed ID: 22227229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children.
    Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R
    Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule.
    Chen CC; Chang MH; Lee HC; Twu SJ; Safary A
    Acta Paediatr Taiwan; 1999; 40(3):157-60. PubMed ID: 10910606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.
    Cooper CL; Davis HL; Angel JB; Morris ML; Elfer SM; Seguin I; Krieg AM; Cameron DW
    AIDS; 2005 Sep; 19(14):1473-9. PubMed ID: 16135900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C.
    Wiedmann M; Liebert UG; Oesen U; Porst H; Wiese M; Schroeder S; Halm U; Mössner J; Berr F
    Hepatology; 2000 Jan; 31(1):230-4. PubMed ID: 10613751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.